Results 151 to 160 of about 79,213 (303)

Cholangiocarcinoma

, 2015
Cholangiocarcinoma presents a challenge for cancer specialists all over the world. Neoplasia of the biliary tract are rare, accounting for approximately 3% of all gastrointestinal tumours with an incidence of about 3 per 100,000; but rate have been ...
BRANDI, GIOVANNI, ERCOLANI, GIORGIO
core  

Impact of Single Viable Hepatocellular Carcinoma ≤ 3 cm on Survival After Liver Transplantation

ANZ Journal of Surgery, EarlyView.
An Australian multi‐centre cohort study shows significantly lower 5‐year HCC‐specific mortality for those with no viable disease compared to those with a single viable tumour ≤ 3 cm, on imaging prior to transplantation. A lower AFP level and complete response on mRECIST criteria also reduced risk.
Lauren C. Y. Tang, Eunice Lee, Avik Majumdar, Ted Stoklosa, Danny Con, William Chung, Emily Nash, Adam Testro, Michael Fink, Simone Strasser, Ken Liu, David G. Bowen, Marie Sinclair   +12 more
wiley   +1 more source

Pancreatic Invasion in Distal Cholangiocarcinoma Is a Poor Prognostic Factor: A New Approach Integrating Tumor Depth of Invasion

ANZ Journal of Surgery, EarlyView.
This study revealed that the combination of DOI > 4 mm and pancreatic invasion is an independent predictor of poor prognosis in distal cholangiocarcinoma. Incorporating pancreatic invasion into DOI‐based classification may improve prognostic assessment beyond the current AJCC staging system.
Hirokazu Ogasawara, Tadashi Yoshizawa, Kenta Ogasawara, Daiki Kasai, Shintaro Goto, Hayato Nagase, Norihisa Kimura, Keinosuke Ishido, Hiroshi Kijima, Kenichi Hakamada   +9 more
wiley   +1 more source

Meta‐Analysis: Safety and Effectiveness of Advanced Therapies in Inflammatory Bowel Disease Patients With Concomitant Primary Sclerosing Cholangitis

Alimentary Pharmacology &Therapeutics, EarlyView.
Advanced IBD therapies appear safe and effective in PSC‐IBD. However remission and response rates appear numerically attenuated compared to IBD‐only populations. Created in BioRender (https://BioRender.com/h9bxgij). ABSTRACT Background Inflammatory bowel disease (IBD) associated with primary sclerosing cholangitis (PSC) is a distinct phenotype (PSC‐IBD)
Amera Elzubeir, Anjana Kumar, Alistair McArdle, Emily Holden, Leo Alexandre, Simon Rushbrook, Kate D. Lynch   +6 more
wiley   +1 more source

Eosinophilic Oesophagitis and Incidence of Gastrointestinal Cancer: A Population‐Based Cohort Study

Alimentary Pharmacology &Therapeutics, EarlyView.
Among 9115 patients with eosinophilic oesophagitis in Denmark, excess gastrointestinal cancer in the first year after diagnosis most likely reflected diagnostic work‐up. Beyond 1 year, oesophageal adenocarcinoma and hepatocellular carcinoma remained more frequent than expected; most patients with oesophageal cancer had prior Barrett's oesophagus ...
Gencer Kurt, Dóra Körmendiné Farkas, Evan S. Dellon, Elizabeth T. Jensen, Henrik Toft Sørensen   +4 more
wiley   +1 more source

Updates in Diagnosis and Endoscopic Management of Cholangiocarcinoma

Cholangiocarcinoma (CCA) is an adenocarcinoma originating from the epithelial cells of the bile ducts/hepatocytes or peribiliary glands. There are three types of cholangiocarcinoma: intrahepatic, perihilar and distal.
Ecaterina Mihaela Rînja, Gabriel Constantinescu, Oana Mihaela Plotogea, Vasile Sandru, Christopher Pavel, Roxana-Luiza Caragut, Madalina Ilie, Afrodita Panaitescu, Teodor Cabel, Deniz Günșahin   +9 more
core   +1 more source

Targeting KRAS for cancer therapy

British Journal of Pharmacology, EarlyView.
In recent years, therapeutics targeted against KRAS proto‐oncogene GTPase (KRAS)‐mutant cancers have seen significant progress. Herein we outline the biology and epidemiology of KRAS alterations at the lineage and allele levels, reviewing the clinical evidence for KRASG12C inhibition from the discovery of the recessive switch pocket to sotorasib ...
Jianlong Jia, Ruonan Liu, Tonia A. Adamide, Isis E. Fernandez, Georgios T. Stathopoulos   +4 more
wiley   +1 more source

Real‐World Safety and Efficacy of Pola‐R‐CHP in Previously Untreated DLBCL: POLASTAR Interim Analysis of 500 Patients

Cancer Science, EarlyView.
In this analysis of a diverse cohort of 500 patients with previously untreated DLBCL in a real‐world clinical setting, Pola‐R‐CHP demonstrated high response rates at end‐of‐treatment, which were consistent among the overall population, in patients > 80 years and regardless of International Prognostic Index status and cell of origin subtypes.
Takahiro Kumode, Hitomi Sawa, Kohta Miyawaki, Atsushi Satake, Nobuhiro Kanemura, Ritsuro Suzuki, Yuki Fujiwara, Yasuhiro Nagate, Shuichi Ota, Takahiro Fujino, Hideki Goto, Noriko Fukuhara, Mamiko Sakata‐Yanagimoto, Koji Izutsu, Momoko Nishikori, Hirohiko Shibayama, Daisuke Ennishi, Takayuki Shimose, Mai Asai, Itaru Matsumura, Koichi Akashi, Koji Kato   +21 more
wiley   +1 more source

LAMC2+ Epithelial Cells Drive Bladder Cancer Progression and Predict Immunotherapy Response via SERPINB3/STAT3/CD44 Axis

Cancer Science, EarlyView.
This study identified LAMC2+ epithelial cells through single‐cell sequencing and found that high expression of LAMC2 is associated with the malignant progression of bladder cancer. HdWGCNA and transcriptome sequencing revealed the SerpinB3/STAT3/CD44 axis. Diosmetin was selected as a potential LAMC2 inhibitor.
Yutong Chen, Yunzhong Jiang, Zezhong Yang, Minxuan Jing, Wentai Wu, Jiale He, Lu Wang, Minghai Ma, Yaodong Zhang, Min Wang, Jianpeng Li, Yuanchun Pu, Bingliang He, Yanjia Liu, Kaibo Mi, Hang Liu, Mengzhao Zhang, Jinhai Fan   +17 more
wiley   +1 more source

CircHECTD1 Promotes Cholangiocarcinoma Progression Through Interaction With SFPQ to Induce Autophagy

Cancer Science, EarlyView.
CircHECTD1 directly interacts with SFPQ to upregulate ATG12 expression, thereby activating autophagy and promoting cholangiocarcinoma progression. This study uncovers a noncanonical circRNA–RNA‐binding protein regulatory mechanism and provides a potential therapeutic target for cholangiocarcinoma.
Shouwen Zhao, Shanshan Jiang, Xutong Wang, Kai Cui, Zhilei Cao, Le Zhang, Zhiqiang Wei, Yuping Ma, Han Hao, Kunpeng Zhang, Jiamin Zhang, Tianyu Dong   +11 more
wiley   +1 more source